Eureka Forbes Limited enhances its manufacturing capability with a strategic partnership with Dixon Technologies India Limited
Business Wire India
Eureka Forbes Limited, one of India's leading health and hygiene brands, is proud to announce its strategic partnership with Dixon Technologies (India) Limited (DTIL), a leader in electronic manufacturing services (EMS).
This collaboration marks an important step in expanding Eureka Forbes' Vacuum Cleaner port f olio by assembly/manufacture & supply of robotic vacuum cleaners, reinforcing its position as a trusted name in Indian households.
Under this partnership, DTIL will produce a range of Robotic Vacuum Cleaners for Eureka Forbes leveraging its cutting-edge facilities and extensive manufacturing expertise. Dixon's ISO-certified plants will ensure that the Eureka Forbes robotic vacuum cleaners meet rigorous standards of durability, quality, and innovation. This collaboration aligns with Eureka Forbes' vision of delivering value-driven, high-performing, health-tech products that cater to the evolving needs of Indian consumers.
Talking about the partnership, Mr. Pratik Pota, MD & CEO, Eureka Forbes Ltd., said, 'At Eureka Forbes, we are committed to delivering innovative, high-performing products that enrich the lives of our consumers. Our strategic partnership with Dixon Technologies is a testament to this commitment and a significant step towards strengthening our Make in India vision. By combining Eureka Forbes's deep consumer insight and innovation prowess with Dixon's manufacturing excellence, we aim to accelerate our presence in the robotic vacuum cleaner category and bring cutting-edge, locally made solutions to Indian homes.'
Mr. Atul B. Lall, Vice Chairman and Managing Director, Dixon Technologies (India), added , 'We are pleased to formalize our strategic partnership with Eureka Forbes, a brand synonymous with trust and innovation in home appliances segment. This agreement marks a significant milestone for our company as we expand our capabilities in the homecare segment. By combining our advanced manufacturing expertise with Eureka Forbes's deep market understanding and product leadership, we aim to deliver high-quality vacuum cleaners that meet the evolving needs of consumers and market. We see this as the beginning of a long-term association that will drive value for both organizations and ultimately benefit customers across markets.'
Dixon Technologies (India) Limited is the largest home grown design-focused and solutions company engaged in manufacturing products in the consumer durables, lighting and mobile phones markets in India. Their diversified product port f olio includes (i) Consumer electronics like LED TVs; (ii) Home appliances like washing machines; (iii) Lighting products like LED bulbs and tube lights, down lighters; (iv) Mobile phones; and (v) Wearables and Hearables(vi) Refrigerators (vii) Telecom and IT Hardware products. Dixon also provides solutions in reverse logistics i.e., repair and refurbishment services of LED TV panels. The company is renowned for its high-quality standards, ethical business practices and commitment, making it a preferred partner across various industry verticals.
Through this collaboration, Eureka Forbes aims to further elevate its product offerings, strengthen its presence in the robotic vacuum market, and continue its mission to become a household name across India.
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
6 hours ago
- Hamilton Spectator
Vladimir Guerrero Jr. just got a custom bat from an Ontario company. Here's the story behind it
The winning Toronto Blue Jays have been the talk of town as of late, and the same could be said about Ontario-based bat company Backyard Bats, which has created a buzz in the baseball world. A custom-made bat from Backyard Bats, a Windsor-based company, is Blue Jays' superstar Vladimir Guerrero Jr.'s newest toy at the ballpark. A post shared by Backyard (@backyardbatco) In 2004, in a backyard shed in Windsor, Ont., Paul LaMantia was hand-spinning bats out of a passion for baseball. His best friend and college baseball teammate, Ryan LaPensee, a former Major League Baseball player for the Arizona Diamondbacks, reached out to LaMantia last spring, with a vision of taking the handspun wood bats to the next level. Their mission was 'to provide players with the highest grade luxury equipment available in the baseball industry today on both sides of the border,' said the company website . By December 2024, that dream became a reality. The brand was approved by the big leagues, becoming MLB-certified, and the bats were ready to get into the hands of professional players. A post shared by Backyard (@backyardbatco) During this year's spring training, LaPensee met Guerrero Jr. and gave him a sample bat to test. 'My jaw was on the floor with how far he could hit the baseball with the bat,' LaPensee said after Guerrero Jr.'s test run. Blue Jays manager John Schneider, whose brother is the COO of the company, wanted to get the bat into his star batter's hands, said LaPensee. So on Friday, July 18, LaPensee was at the Rogers Centre in Toronto to hand-deliver four custom bats ahead of the Blue Jays' game against the San Francisco Giants. Guerrero Jr. used it during batting practice, while teammates George Springer and Alejandro Kirk watched. 'He had a big smile on his face,' LaPensee said after viewing batting practice along with his family. 'To hear that loud bang off the bat was cool,' he added. The custom-made 'VGJ27' bat would later be used in a live game that evening, where the Blue Jays shut out the Giants 4-0. A post shared by VLADIMIR GUERRERO JR (@vladdyjr27) Backyard Bats has also found its way into the hands of big league stars like Bryce Harper and Nick Castellanos, and Blue Jay Davis Schneider, among others. When asked how many other stars in the league are using the bats, LaPensee admitted he's already 'lost count.' The bats range from range from $99 for youth bats, to $209 for custom pro batch bats. Guerrero Jr. and the Blue Jays, who currently hold first place in the AL East division, take on the New York Yankees tonight (July 23) in Toronto, before heading to Detroit to play the Tigers in a four-game series that starts on Thursday, July 24 at Comerica Park. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Business Wire
6 hours ago
- Business Wire
Biote Schedules Second Quarter 2025 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) ('Biote' or the 'Company'), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide second quarter financial results on Wednesday, August 6, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Second Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, found here, shortly after the event concludes. About Biote Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words 'may,' 'can,' 'should,' 'will,' 'estimate,' 'plan,' 'project,' 'forecast,' 'intend,' 'expect,' 'hope,' 'anticipate,' 'believe,' 'seek,' 'target,' 'continue,' 'could,' 'might,' 'ongoing,' 'potential,' 'predict,' 'would' and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers' sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including international tariffs and the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the 'Risk Factors' section of Biote's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on March 14, 2025, Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, filed with the SEC on May 9, 2025, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
Time Business News
8 hours ago
- Time Business News
The Future of Regenerative Medicine Unfolds
Synthetic stem cell lab-engineers are cell mimic designed to repeat the therapeutic effects of natural stem cells without living cell therapy, such as immune rejection or risks associated with tumor formation. These synthetic options often use biometrics or nanoparticles to distribute regenerative signals and therapeutic molecules. Market safe for synthetic stem cells, more scalable regenerative medical solutions, progression in biometric and nanotechnology and increasing demand due to increasing demand due to increased prevalence of chronic diseases and tissue injuries, requiring innovative, low -risk treatment options. Key Growth Drivers and Opportunities Progression in Biometric and Nanotechnology: Progress in biometrics and nanotechnology is significantly running the development of the synthetic stem cell market by enabling the accurate design and construction of the cell-mimicking system repeating natural stem cells. Nanotechnology enhances targeted distribution, bio -purpose and controlled release of therapeutic agents, while biometric advanced cell surface helps to mimic the surface markers and signaling the necessary routes for tissue regeneration. These innovations not only improve the safety and efficacy of synthetic stem cell therapy, but also make them more scalable and adaptable for various clinical applications, which accelerate their adoption in regenerative therapy. Challenges The synthetic stem cell market faces several borders, including challenges in completely imitating complex biological functions and adaptability of natural stem cells. Issues such as limited long-term efficacy, potential immune reactions and scalability of high-loyal synthetic cells can obstruct widely adopting. Additionally, the requirement of regulator uncertainty and extensive clinical verification slows down commercialization and integration in mainstream treatments. These obstacles must be addressed to feel the full potential of synthetic stem cell technologies in regenerative medicine. Innovation and Expansion Next-Gen Stem Cell Products for Regenerative Medicine Revealed by Bioserve India In July 2024, with great pleasure, Bioserve India announced the arrival of its cutting-edge stem cell products in India. With the help of these new REPROCELL solutions, the Indian market will see advances in regenerative medicine and therapeutic discoveries as well as innovation in scientific research and medication development. The market for stem cells is a quickly expanding sector that includes a variety of goods and services. Many sectors of the stem cell market are involved in vital tasks such product development, production, and distribution of stem cell treatment. New medicines and improvements in healthcare are anticipated as a result of this launch, which is anticipated to stimulate stem cell research and therapeutic development in India. The First Scientific Development of Synthetic Human Embryos without Sperm or Egg In June 2023, in an innovative development that avoids the need for eggs or sperm, scientists have used stem cells to produce synthetic human embryos. These model embryos, which are similar to those in the early phases of human development, may offer a vital insight into the effects of genetic diseases and the biochemical reasons for repeated miscarriages, according to scientists. As scientists are only legally permitted to nurture embryos in the lab for a maximum of 14 days, the effort is motivated by the desire to help scientists grasp the so-called 'black box' stage of development. Pregnancy scans and research-donated embryos are then used to pick up the development considerably farther along. Inventive Sparks, Expanding Markets The key players operating the synthetic stem cells market involves Sangamo Therapeutics, Athersys, Pluristem Therapeutics, Cellular Biomedicine Group, Vericel, BrainstormCell Therapeutics, Caladrius Biosciences, Cytori Therapeutics, Cesca Therapeutics, VistaGen Therapeutics. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
